A carregar...
Targeting ALK: Precision Medicine Takes On Drug Resistance
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-rearranged malignancies, including non-small-cell lung cancer (NSCLC). However, the clinical benefit of targeting ALK using tyrosine kinase inhibitors (TKIs) is almost universally limited by the emergence of drug resista...
Na minha lista:
| Publicado no: | Cancer Discov |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5296241/ https://ncbi.nlm.nih.gov/pubmed/28122866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1123 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|